Martin Reck
@MartinReck2
Followers
1K
Following
2K
Media
41
Statuses
952
Just published - thanks for an outstanding cooperation! First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCL... https://t.co/a7u36EkYle
@IASLC #lcsm
0
0
4
Looking forward to a great discussion and to see you!
What defined progress in 2025 for targeted therapies and ADCs? At our roundtable, @MartinReck2 will walk through the most influential data in targeted treatments and antibody drug conjugates, highlighting how these advances are reshaping decision making in NSCLC. Together with
0
1
3
With more than 8,500 satellites in orbit, Starlink provides connectivity through harsh weather conditions, network disruptions, and natural disasters. Order online in under 2 minutes.
1K
2K
15K
Which breakthroughs defined SCLC treatment in 2025 and where are we heading? At our roundtable, @charlesrudin will guide us through the most practice relevant updates in SCLC from this year, including data that is shifting how we approach frontline and relapsed disease. Together
0
5
10
Just published - the Northern German Hanse Lung Cancer Screening Trial. Grateful for an outstanding cooperation! Much more to come, but this has been the first step! #LCSM
#Lungenkrebs-Früherkennung: Wählt man die Menschen, die Anspruch auf das Screening haben, nicht nur nach Alter & Rauchhistorie, sondern nach zusätzlichen Kriterien aus, findet man ~20% mehr Krebsfälle. Das zeigt eine Studie von #CharitéBerlin & Partnern 👉 https://t.co/NinZk5av9D
0
0
2
🔔 Save the Date! Join @peters_solange, @charlesrudin and @MartinReck2 for our 2025 Highlights and Year in Review Session. This interdisciplinary session will recap the year’s most important advances in lung cancer care, covering new approvals and breakthroughs in SCLC and
0
6
19
RT @CharuAggarwalMD: What a wonderful trip to @myESMO Grateful to the opportunity to present results of our clinical trials to help patient…
0
1
0
🆙#ESMO25🇩🇪 🔥#LCSM Special Symposium ☑️Optimising the use of IO in the perioperative setting 🎯Clinical factors 🎙️ @MartinReck2
@OncoAlert @myESMO @Larvol
0
12
19
#ESMO25 Highlights of Day 2🔥 Incredible studies presented at the early stage lung orals led by @NReguart & @HendriksLizza - MDT-bridge: neoadj for borderline resectable NSCLC @MartinReck2 - 1L Tarlatamab + ChemoIO in ES SCLC #MartinWermke
#ESMO25 #ESMOAmbassadors @myESMO
1
18
56
🫁 MDT-BRIDGE @MartinReck2 @myESMO In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts. Resection rate 85.7% (94% R0), pCR 27.6%. Outcomes consistent with AEGEAN, even including borderline
1
9
30
Stage III is getting more interesting & probably the future will depend on response (and restaging). Amazing discussion @MartinReck2! Is this a neoadj or a conversion strategy!! Thanks Lizza & Noemi
0
1
4
🆙#ESMO25🇩🇪 🔥#LCSM Proffered paper, non-mets, SCLC ☑️MDT-BRIDGE: Neoadju Chemo-durva▶️Surgery, Surgery▶️Adj durva, CRT▶️Consoli ICI ☑️Initiation of neoadju Durva + Chemo and close MDT F/U could allow⏫pts to receive curative-intent Tx 🎙️ @MartinReck2
@OncoAlert @myESMO @Larvol
🆙#ESMO25 PREVIEW🇩🇪 🔥#LCSM Proffered paper, non-mets ✅MDT-BRIDGE: Neoadju Chemo-ICI▶️Surgery, Surgery▶️Adj ICI, CRT▶️Consoli ICI 🎙️ @MartinReck2
@OncoAlert @myESMO @Larvol
1
8
14
In the Bridge trial 22/28 patients borderline resectable became resectable and 19% had a cPR. Very provocative results. Maybe we can save more patients. @MartinReck2 #ESMO25 #esmo2025
0
2
8
Impressive results from MDT-BRIDGE at #ESMO25 from Dr. @MartinReck2. Pts with resectable or borderline had 2 cycles of durvalumab + chemo then reassessed at MDT. If resectable at start, 95% remained resectable. If borderline, 82% were then felt to be resectable. #ESMOAmbassadors
2
40
92
MDT-BRIDGE broaden the population finally considered for surgery in borderline resectable NSCLC with just 2 cycles of neoadjuvant chemo-Durva. 27% pCR with acceptable surgical outcomes. @MartinReck2 showed the importance of longitudinal MTD decisions #ESMO25 #LCSM
1
6
28
Coming together with dear friends at #ESMO25 in Berlin! @MartinReck2 @JessicaMenis @CharuAggarwalMD @MLJohnsonMD2 @HwakeleeMD @DrJNaidoo @PatelOncology @JordiRemon @DrSanjayPopat @LuisPaz_Ares @PrelajArsela @marinagarassino @LudaBazhenovaMD @FedericoCappuz1 @a_dingemans
0
7
65
Thank you for coming!
Coming together with dear friends at #ESMO25 @MartinReck2 @JessicaMenis @CharuAggarwalMD @MLJohnsonMD2 @HwakeleeMD @DrJNaidoo @PatelOncology @JordiRemon @DrSanjayPopat @LuisPaz_Ares
0
0
2
What an absolute honor to discuss #ctDNA MRD use in optimizing perioperative immunotherapy in early stage NSCLC @myESMO with @MartinReck2 #LCSM @OncoAlert Dr. Jan von der Thusen and Dr. Johan Filip Vansteenkiste
0
9
37
🫁 Top #LungCancer abstracts at #ESMO25 via High5OncologyTV: 🔹 LBA4: Ivonescimab vs Tislelizumab (sqNSCLC) 🔹 LBA5: Sac-TMT vs chemo (EGFRm NSCLC) 🔹 2757O: Tarlatamab + chemo-IO (ES-SCLC) 🔹 LBA65: Neoadj Durva + CT (IIB–IIIB NSCLC) 🔹 LBA74: Zongertinib 1L (HER2m) 🔹 LBA69:
0
12
16
FDA 🇺🇸Approval https://t.co/KVMu5YiyHi On October 2, 2025, the FDA approved lurbinectedin with atezolizumab as maintenance therapy for adults with extensive-stage small cell lung cancer (ES- #SCLC )that has not progressed after initial atezolizumab-based chemotherapy. In the
1
20
49
Thank you for the privilege to be included! Warm welcome to an outstanding ESMO program this year in Germany 🇩🇪!😀 @myESMO @OncoAlert
The OncoAlert #LungCancer Faculty, led by Dr. Hidehito Horinouchi 🇯🇵 as well as Dr Biagio Ricciuti 🇺🇸 and Dr. Gil Morgan🇺🇸 , have selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin 🇩🇪 Picked using a Delphi System to establish our picks.
0
5
12